Physician profile
Heath Long
NPI 1265085385
$11,165.64
in general payments reported to CMS, 2019-2025
32 companies · $2,279 in 2025
The $2,279 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,504 · 2022: $2,484 · 2023: $2,910 · 2024: $1,988 · 2025: $2,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,177.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,158.74 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,399.74 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,149.58 | 2021-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,008.81 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Scientific Affairs, LLC | $708.57 | 2021-2025 | Stelara, Tremfya |
| Celgene Corporation | $389.15 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $357.65 | 2021-2023 | Ocaliva |
| Gilead Sciences, INC. | $353.79 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $260.31 | 2023-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $253.58 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $211.85 | 2021-2024 | Injectafer |
| Qol Medical, LLC | $183.37 | 2023-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $163.55 | 2021-2023 | |
| Genzyme Corporation | $161.05 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $134.24 | 2022-2025 | Dupixent |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $130.32 | 2022-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $129.64 | 2021-2023 | Dificid |
| Pharmacosmos Therapeutics INC. | $119.52 | 2023 | Monoferric |
| Evoke Pharma, INC. | $111.46 | 2022 | |
| Ardelyx, INC. | $105.31 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $104.57 | 2022-2024 | Rebyota |
| Organon LLC | $87.40 | 2023-2024 | Hadlima, Renflexis |
| Pfizer INC. | $76.86 | 2022-2025 | |
| Redhill Biopharma INC. | $75.45 | 2021-2022 | |
| Lilly USA, LLC | $61.99 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $59.60 | 2025 | Rezdiffra |
| Fresenius Kabi USA, LLC | $51.87 | 2023-2024 | Idacio |
| Braintree Laboratories, INC. | $49.55 | 2022-2023 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $43.24 | 2022-2023 | Linzess |
| Intra-Sana Laboratories | $27.97 | 2022-2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Medtronic, INC. | $21.70 | 2021 | |
| Amgen INC. | $15.21 | 2023 | Avsola, Amjevita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heath Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.